Biochemical outcome for hormone-naive patients with Gleason score 3+4 versus 4+3 prostate cancer undergoing permanent prostate brachytherapy

Author： Merrick G.S. Butler W.M. Galbreath R.W. Lief J.H. Adamovich E.

Publisher： Elsevier

ISSN： 0090-4295

Source： Urology, Vol.60, Iss.1, 2002-07, pp. : 98-103

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Does the outcome of prostate cancer patients with large prostates differ from small prostate size in permanent seed, low dose-rate brachytherapy?

By Aaltomaa Sirpa H. Kataja Vesa V. Räty Atte Palmgren Jan-Erik Lahtinen Tapani

Scandinavian Journal of Urology and Nephrology, Vol. 45, Iss. 5, 2011-11 ,pp. : 339-345

Informa Healthcare

Access to resources Recommend Favorite

Use of PC-SPES, a commercially available supplement for prostate cancer, in a patient with hormone-naive disease

By Moyad M.A. Pienta K.J. Montie J.E.

Urology, Vol. 54, Iss. 2, 1999-08 ,pp. : 319-323

Elsevier

Access to resources Recommend Favorite

The Impact of Prostate Volume Following Neoadjuvant Androgen Deprivation on Quality of Life and Voiding Symptoms in Patients Undergoing Permanent Prostate Brachytherapy

By Krupski T. Bissonette E.A. Petroni G.R. Theodorescu D.

European Urology, Vol. 43, Iss. 5, 2003-05 ,pp. : 467-472

Elsevier

Access to resources Recommend Favorite

Probability of biochemical recurrence by analysis of pathologic stage, gleason score, and margin status for localized prostate cancer

By Khan M.A. Partin A.W. Mangold L.A. Epstein J.I. Walsh P.C.

Urology, Vol. 62, Iss. 5, 2003-11 ,pp. : 866-871

Elsevier

Access to resources Recommend Favorite

Permanent brachytherapy as salvage treatment for recurrent prostate cancer

By Beyer D.C.

Urology, Vol. 54, Iss. 5, 1999-11 ,pp. : 880-883

Elsevier

Access to resources Recommend Favorite